Related Experiment Video

Updated: Jul 4, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Drug-induced immune thrombocytopenic purpura secondary to sunitinib

M Trinkaus1, M Trudeau, J Callum

  • 1Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON.

Current Oncology (Toronto, Ont.)
|July 4, 2008
PubMed

Insights

Sunitinib, a cancer drug, can cause low platelets (thrombocytopenia). This case report is the first to show that sunitinib may trigger an immune response leading to this side effect.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Sunitinib is an oral multi-targeted tyrosine kinase inhibitor used for various solid tumors.
  • Common side effects of sunitinib include thrombocytopenia, often attributed to myelosuppression.
  • The exact mechanism of sunitinib-induced thrombocytopenia requires further investigation.

Purpose of the Study:

  • To report the first case of immune-mediated thrombocytopenia secondary to sunitinib administration.
  • To highlight a potential alternative mechanism for sunitinib-induced thrombocytopenia.

Main Methods:

  • Case report presentation.
  • Review of clinical data and laboratory findings.
  • Analysis of potential immune mechanisms.

Main Results:

  • The patient developed thrombocytopenia following sunitinib treatment.
  • Evidence suggests an immune-mediated etiology rather than direct myelosuppression.
  • This finding expands the understanding of sunitinib's adverse effects.

Conclusions:

  • Immune-mediated thrombocytopenia is a potential adverse effect of sunitinib.
  • Clinicians should consider immune mechanisms when managing thrombocytopenia in patients on sunitinib.
  • Further research is warranted to confirm and elucidate this mechanism.
Keywords:
Breast cancersunitinibthrombocytopenia

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...